NYSE USD

ADC Therapeutics SA (ADCT)

1.9700

-0.1800

(-8.37%)

At close: May 21 at 4:00:02 PM EDT

2.0100

+0.04

+(2.03%)

Pre-Market: 5:51:27 AM EDT

Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results

ADC Therapeutics SA ( NYSE:ADCT ) investors will be delighted, with the company turning in some strong numbers with its...

Simply Wall St. 4 days ago

ADCT
-8.37%
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data

The company has pulled the drug candidate from development, leaving it with one remaining clinical asset.

Clinical Trials Arena 6 days ago

ADCT
-8.37%
ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two upcoming investor conferences:

PR Newswire 6 days ago

ADCT
-8.37%
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 5.26% and 26.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

ADCT
-8.37%
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2025, and provided recent operational updates.

PR Newswire 7 days ago

ADCT
-8.37%
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data presentations from the LOTIS-7 Phase 1b clinical trial evaluating ZYNLONTA (loncastuximab tesirine-lpyl) in combination with glofitamab in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Updated results will be shared at the European Hematology Association 2025 Congress (EHA2025) taking place in Milan, Italy with an or

PR Newswire 7 days ago

ADCT
-8.37%
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

Zymeworks (ZYME) delivered earnings and revenue surprises of 33.33% and 57.36%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 13 days ago

ADCT
-8.37%
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Wednesday, May 14, 2025, at 8:30 a.m. EDT to report financial results for the first quarter 2025 and provide operational updates.

PR Newswire 13 days ago

ADCT
-8.37%
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of -29.41% and 88.19%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 20 days ago

KURA

ADCT
-8.37%
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of 4.55% and 3.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 21 days ago

ACIU

ADCT
-8.37%
Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 22 days ago

AGEN

ADCT
-8.37%
ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ADC Therapeutics (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 23 days ago

ADCT
-8.37%
ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based antibody drug conjugates (ADCs) targeting Claudin-6 (CLDN6), prostate-specific membrane antigen (PSMA), and Alanine, Serine, Cysteine Transporter 2 (ACST2) as presented at the American Association for Cancer Research (AACR) Annual Meeting 2025.

PR Newswire 23 days ago

ADCT
-8.37%
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 128,600 of the Company's common shares to two new employees on April 1, 2025 (each, a "Grant").

PR Newswire last month

ADCT
-8.37%
ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will present a company overview at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 8:00 a.m. ET.

PR Newswire last month

ADCT
-8.37%
ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...

Despite flat revenue growth, ADC Therapeutics SA (ADCT) strengthens its financial position with reduced losses and promising trial data.

GuruFocus.com last month

ADCT
-8.37%
ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics ( NYSE:ADCT ) Full Year 2024 Results Key Financial Results Revenue: US$70.8m (up 1.8% from FY 2023...

Simply Wall St. last month

ADCT
-8.37%
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 17.14% and 14.01%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ADCT
-8.37%
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent operational updates.

PR Newswire last month

ADCT
-8.37%
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced abstracts detailing multiple preclinical programs have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois.

PR Newswire last month

ADCT
-8.37%

Performance Overview

Return	ADCT	S&P 500 (^GSPC)
YTD	-1.01%	-0.63%
1-Year	-47.18%	+9.83%
3-Year	-72.06%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

ADC Therapeutics SA (ADCT)

Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results

ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data

ADC Therapeutics to Present at Upcoming Investor Conferences

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML)

Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates

ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025

Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

ADC Therapeutics SA (ADCT) Q4 2024 Earnings Call Highlights: Navigating Challenges and ...

ADC Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates

ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025

Performance Overview